Search research articles
Contact Us
Filters
Showing results (131-140 of 141) with videos related to
Page
of 15
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
January 1, 1991
Phase I/II evaluation of effervescent and enteric coated oral pamidronate for bone metastases
R E Coleman, L Y Dirix, D Dodwell, et al.
International Journal of Food Microbiology
|
January 16, 2009
Prevalence of methicillin-resistant Staphylococcus aureus in meat
E de Boer, J T M Zwartkruis-Nahuis, B Wit, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 6, 2003
18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec)
S Stroobants, J Goeminne, M Seegers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 15, 2000
Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group
A Le Cesne, I Judson, D Crowther, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 7, 2000
Vascular targeting of solid tumours: a major 'inverse' volume-response relationship following combretastatin A-4 phosphate treatment of rat rhabdomyosarcomas
W Landuyt, O Verdoes, D O Darius, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 6, 2003
Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study
J Verweij, A van Oosterom, J-Y Blay, et al.
Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation
|
October 19, 2011
Noninvasive detection of epicardial and endocardial activity of the heart
T F Oostendorp, P F H M van Dessel, R Coronel, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 31, 2000
Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group
O S Nielsen, I Judson, Q van Hoesel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 22, 2005
Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial
A Le Cesne, J Y Blay, I Judson, et al.
American Journal of Clinical Oncology
|
October 20, 2000
Carcinoma of the kidney, testis, and rare urologic malignancies
Z Petrovich, L V Baert, L W Brady, et al.
Page
of 15
Search research articles
Search
Showing results (131-140 of 141) with videos related to
Sort By:
Page
of 15
European Journal of Cancer (Oxford, England : 1990)
|
January 1, 1991
Phase I/II evaluation of effervescent and enteric coated oral pamidronate for bone metastases
R E Coleman, L Y Dirix, D Dodwell, et al.
International Journal of Food Microbiology
|
January 16, 2009
Prevalence of methicillin-resistant Staphylococcus aureus in meat
E de Boer, J T M Zwartkruis-Nahuis, B Wit, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 6, 2003
18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec)
S Stroobants, J Goeminne, M Seegers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 15, 2000
Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group
A Le Cesne, I Judson, D Crowther, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 7, 2000
Vascular targeting of solid tumours: a major 'inverse' volume-response relationship following combretastatin A-4 phosphate treatment of rat rhabdomyosarcomas
W Landuyt, O Verdoes, D O Darius, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 6, 2003
Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study
J Verweij, A van Oosterom, J-Y Blay, et al.
Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation
|
October 19, 2011
Noninvasive detection of epicardial and endocardial activity of the heart
T F Oostendorp, P F H M van Dessel, R Coronel, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 31, 2000
Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group
O S Nielsen, I Judson, Q van Hoesel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 22, 2005
Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial
A Le Cesne, J Y Blay, I Judson, et al.
American Journal of Clinical Oncology
|
October 20, 2000
Carcinoma of the kidney, testis, and rare urologic malignancies
Z Petrovich, L V Baert, L W Brady, et al.
Page
of 15